Novartis cries foul in India
The Spicy India IP blog is reporting that there has been a further twist in Novartis’s challenge to the Indian Patent Office’s decision not to grant protection to its anti-cancer drug Glivec. The drug company has formally objected to the presence of…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now